期刊文献+

高效液相色谱法测定替格瑞洛原料药中基因毒性杂质的含量

Determination of Genotoxic Impurity in Bulk Drug of Ticagrelor by HPLC
下载PDF
导出
摘要 目的建立替格瑞洛原料药中基因毒性杂质N的测定方法。方法采用高效液相色谱(HPLC),选用C_(18)色谱柱(Agilent Zorbax SB C_(18),150 mm×4.6 mm,5μm),乙腈为流动相A,磷酸盐缓冲液为流动相B,梯度洗脱,流速1.0 mL·min^(-1),检测波长210 nm,柱温35℃。结果上述色谱条件下,基因毒性杂质N与其他组分分离完全;在0.0107~0.0485μg·mL^(-1)浓度范围内,峰面积(A)与杂质N浓度(C)有良好的线性关系,回归方程为A=40722C+9.9875(r=0.9996),平均回收率为99.8%,RSD为0.61%。结论该方法稳定、可靠、重现性好,可用于替格瑞洛原料药中基因毒性杂质N的含量测定。 OBJECTIVE To develop an method for determination of the genotoxic impurity N in bulk drug of ticagrelor.METHODS The determination was performed by HPLC on a C_(18) column(Aglient Zorbax SB C_(18),150 mm×4.6 mm,5μm)with acetonitrile as mobile phase A and phosphate buffer solution as the mobile phase B by gradient elution.The flow rate was 1.0 mL·min^(-1),the detection wavelength was 210 nm,and the column temperature was kept at 35℃.RESULTS The peak of impurity N and other components could be separated well.There was a good linear relationship between peak area(A)and impurity N concentration(C)in the concentration range of 0.0107-0.0485μg·mL^(-1).The regression equation was A=40722 C+9.9875(r=0.9996),the average recovery was 99.8%and the RSD was 0.61%.CONCLUSION The method is stable,reliable and reproducible and can be used in the determination of the genotoxic impurity N in bulk drug of ticagrelor.
作者 蔡丽朋 周琪 CAI Li-peng;ZHOU Qi(Jiangxi Qingfeng Pharmaceutical Ltd,Ganzhou 341000,China)
出处 《海峡药学》 2022年第5期53-56,共4页 Strait Pharmaceutical Journal
关键词 替格瑞洛 原料药 基因毒性杂质 高效液相色谱法 含量测定 Ticagrelor Bulk drug Genotoxic impurity HPLC Determination
  • 相关文献

参考文献6

二级参考文献57

  • 1Rivera J, Lozano ML, Navarro-N/Jfiez L, et al. Platelet recep- tors and signaling in the dynamics of thrombus formation[J]. Haematologica, 2009,94 (5) : 700-711.
  • 2Yusuf S, Zhao F, Mehta SIR, et al. Effects of clopidogrel in ad- dition to aspirin in patients with acute coronary syndromes without ST-segment elevation [J ]. N Engl J Med, 2001,345 (7) : 494-502.
  • 3Abergel E, Nikolsky E. Ticagrelor: an investigational oral an- tiplatelet treatment for reduction of major adverse cardiac e- vents in patients with acute coronary syndrome [J ]. Vasc Health Risk Manag,2010 ,6:963 -977.
  • 4中国网.治疗ASC患者的新选择一倍林达中国上市获批准[EB/OL].http://www.chinadaily.corn.cn/hqcj/201211/30/content-15975879.htm.20121130.20130110.
  • 5Teng R, Oliver S, Hayes MA, et al. Absorption, distribution, metabolism, and excretion of ticagrelor in healthy subjects[J].Drug Metab Dispos,2010 ,38(9):1514-21.
  • 6Astra Zeneca. Brilinta, Brilique (ticagrelor) [ EB/OL]. http:// www. astrazeneca, com/Medicines/Car-diovascular/Product/ Brilinta-Brilique. 2013-01-10.
  • 7Teng R, Butler K. Pharmacokinetics, pharmacodynamics, safety and tolerability of multiple ascending doses of ticagrelor in healthy volunteers[J].Br J Clin Pharmacol, 2010 , 70( 1 ) : 65-77.
  • 8AstraZeneca. Brilinta (ticagrelor) Tablets, prescribinginforma- tion[EB/OL], http..//wwwl, astrazenecus, com/p-i/brilinta. pdf. 2011-07-20. 2012-09-28.
  • 9Zhou D, Andersson TB, Grimm SW. In vitro evaluation of po- tential drug-drug interactions with ticagrelor: cytochrome P450 reaction phenotyping, inhibition, induction, and differential ki- neties[J]. Drug Metab Dispos, 2011 , 39 (4) : 703-10.
  • 10Storey RF, Angiolillo DJ, Patil SB, el al. Inhibitory effects ofticagrelor compared with clopidogrel on platelet function in pa- tients with acute coronary syndromes:the PLATO (PI.ATelet inhibition and patient Outcomes)PLATELET substudy[J]. J Am Coil Cardiol,2010 ,56(18) : 1456- 62.

共引文献138

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部